Dimerix (ASX:DXB) Successfully Completes IDMC Review for ACTION3 Phase 3 Trial
Trial Progress
Dimerix completed the sixth scheduled Independent Data Monitoring Committee (IDMC) review of the ACTION3 Phase 3 clinical trial, recommending the trial continue unchanged.
Safety Update
The IDMC noted no safety concerns to date, confirming the strong safety profile of DMX-200.
Executive Comments
Dr David Fuller, Chief Medical Officer, stated, “This encouraging recommendation of the IDMC confirms the strong emerging safety profile of DMX-200 and suggests that DMX-200 does not add a burden of side effects to patients, compared to commonly used treatments such as high dose steroids and immunosuppressants. DMX-200 represents a real hope for the many patients suffering from FSGS kidney disease who currently have limited treatment options.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
